arrowhead läuft - zu recht
Wed, April 27, 2022, 1:30 PM
https://finance.yahoo.com/news/...als-host-pulmonary-r-113000587.html
ASADENA, Calif., April 27, 2022--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a pulmonary research & development (R&D) day to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates from 10:00 a.m. to 1:00 p.m. ET on May 26, 2022, in New York City. The R&D day will feature presentations from key opinion leaders, Mario Castro, M.D., MPH (University of Kansas Medical Center) and Matthias Salathe, M.D. (University of Kansas Medical Center), who will discuss the current treatment landscape and unmet medical need in treating patients with muco-obstructive and inflammatory pulmonary diseases.
The R&D day will also feature presentations from the Arrowhead team, who will discuss the company’s proprietary pulmonary Targeted RNAi Molecule (TRiMTM) platform and the therapeutic potential of the investigational RNAi candidates, ARO-MUC5AC and ARO-RAGE, in these disease areas:
ARO-MUC5AC is designed to reduce expression of mucin 5AC (MUC5AC) as a potential treatment for various muco-obstructive pulmonary diseases
ARO-RAGE is designed to reduce expression of the receptor for advanced glycation end products (RAGE) as a potential treatment for various obstructive inflammatory pulmonary diseases
Drs. Castro and Salathe, and the Arrowhead team will be available to answer questions following the event.
This event is intended for institutional investors, sell-side research analysts, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To request a seat, please click here to register.
A copy of the presentation materials and a webcast link will be available on the Events and Presentations page under the Investors section of the Arrowhead website.
Wed, August 17, 2022 at 1:30 PM
https://finance.yahoo.com/news/...y-clearance-initiate-113000051.html
wieder sehr gute Ergebnisse.
Und verschiedene Phasen 3 stehen an.
Die gehen ihren Weg und der Kurs wird folgen
ARWR verkauft Lizenzbeteiligung an Olpasiran
an $RPRX für 250 Mio. $ und zukünftige Meilensteine
https://www.fiercebiotech.com/biotech/...prized-amgen-partnered-heart
Optionen
| Boardmail an "Vassago" |
Wertpapier: Arrowhead Pharmaceutica |
Zahlen für FY22
- Umsatz 243 Mio. $
- Verlust 173 Mio. $
- Cash 482 Mio. $
- MK 2,96 Mrd. $
https://ir.arrowheadpharma.com/news-releases/...2022-year-end-results
Optionen
| Boardmail an "Vassago" |
Wertpapier: Arrowhead Pharmaceutica |
Tue, December 20, 2022 at 1:30 PM GMT+1
https://finance.yahoo.com/news/...announces-25-million-123000951.html
Wed, December 21, 2022 at 1:30 PM GMT+1
https://finance.yahoo.com/news/...present-topline-data-123000512.html
PASADENA, Calif., December 21, 2022--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda. Fazirsiran is a potential first-in-class investigational RNA interference (RNAi) therapy designed to reduce production of the mutant alpha-1 antitrypsin protein (Z-AAT) as a potential treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency. Fazirsiran is being developed under a collaboration and licensing agreement between Arrowhead and Takeda.
Top line Daten für die Phase 2 und damit die Phase 3.
Dann wird noch interessant, ob die Behörde Fast Lane genehmigt.
man kann auch sagen: na endlich
Es wird eine Phase 3 geben- heißt - 2 Jahre noch, dann irgendwann die Zulassung.
Das ist dem Markt zu weit weg.
https://ir.arrowheadpharma.com/news-releases/...sults-sequoia-phase-2
https://ir.arrowheadpharma.com/static-files/...4773-943a-dbacdfb726a0
https://finance.yahoo.com/news/...-webcast-fiscal-2023-123000104.html
PASADENA, Calif., January 25, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Feb 2, 2023 at 7:30 AM EST
https://ir.arrowheadpharma.com/news-releases/...se-12a-study-aro-mmp7
Definitely not a once in a lifetime type of drug, as there are many fantastic targets for RNAi. I will say, however, that this a unique and very valuable opportunity. Even though IPF is an orphan indication (under 200k patients), all 100k patients in the US are known, as it requires a diagnosis - usually because of some symptoms. Once being diagnosed, life expectancy is about 3 years, as there are no decent treatments - so it's a horrible disease. Another horrible aspect of IPF is that there are approximately 30k new patients diagnosed in the US every year.
MMP7 is also known as "matrilysin" and it has been shown in research as far back as 20 years ago that it is a key regulator of pulmonary fibrosis, except that nobody has been able to knock this gene down - that is, until now.
ARO-MMP7 is now beginning to dose its very first patients, and the hope is that it will work and save lives. If it does work, my guess is that IPF will eventually be no longer classified as an orphan disease, as it is very possible that Arrowhead's drug will grow the IPF population (by keeping them alive) to over 200k patients.
So why is this drug so unique?
1) There will be no difficulty in identifying patients, like it will be for AAT. IPF patients are known, so sales and marketing will be a breeze. AAT, however, only around 10-15% of the patients are known (out of 120k), so the challenge for AAT will be to try and identify more prospective patients that are afflicted with AAT.
2) IPF patients will need to take this drug for the rest of their lives, and every year you can add another 30k patients in the US alone. The amount of patients that can be added on a yearly basis for this orphan indication will easily rival the number of patients that get added on larger, non-orphan indications, as typical orphan indication increases are around 5% per year (like it is for AAT).
3) Since this is such a serious condition, and an orphan indication, the cost of this drug should easily surpass $75k per year (I'm guessing it could easily go well into the $200k range). Crunch those numbers and you'll see that you'll easily bring in $10B+ in yearly revenue after 3-5 years on the market. And if the drug works, Accelerated Approval after phase 2 is a no-brainer. At that point, analysts would be giving price targets in the $300+/share range based on this one drug alone. That's right, $300+ based on this one drug alone.
So even though it's an orphan indication, it will theoretically take advantage of a larger, non-orphan population, but also benefit at orphan drug pricing levels, especially since there's currently no competition and it's for an incredibly grave condition.
Realize that all has to go right in order for this to happen. We still don't have proof-of-concept for lung, let alone what the knock-down would be for this drug. I'll tell you this, given these circumstances, it is incredibly exciting.
https://finance.yahoo.com/quote/ARWR/community?p=ARWR
Feb. 06, 2023 2:49 PM ETArrowhead Pharmaceuticals, Inc. (ARWR), JNJBy: Dulan Lokuwithana, SA News Editor
https://seekingalpha.com/news/...ial&utm_source=twitter_automated
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
Feb 6, 2023 at 4:00 PM EST
https://ir.arrowheadpharma.com/news-releases/...al-2023-first-quarter
Wed, February 8, 2023 at 11:34 AM
https://finance.yahoo.com/news/arwr-catalyst-rich-2023-103400004.html
Wed, February 15, 2023 at 1:30 PM
https://finance.yahoo.com/news/...ls-gains-full-rights-123000705.html
Auf eier Folie von der JP Morgen Konferenz steht was von einem Platformdeal?
In der Art Morphosys-Novartis
https://www.morphosys.com/en/news/...-innovative-therapeutic-antibody
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
- Achieved Mean Reductions of 88% in C3 and 91% in AH50
February 28, 2023 07:30 AM Eastern Standard Time
https://www.businesswire.com/news/home/20230228005667/en/
Fri, March 3, 2023
PASADENA, Calif., March 03, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the respiratory/infections panel discussion on March 8, 2023, at 10:30 a.m. ET at the Cowen 43rd Annual Health Care Conference being held in Boston.
https://finance.yahoo.com/news/...-present-43rd-annual-123000016.html
Zahlen für Q1/23
- Umsatz 63 Mio. $
- Verlust 41 Mio. $
- Cash 618 Mio. $
- MK 2,72 Mrd. $
https://ir.arrowheadpharma.com/news-releases/...al-2023-first-quarter
ARWR ist bei mir gedanklich als Übernahmekandidat abgespeichert. Die Frage ist, wann der richtige Zeitpunkt ist hier einzusteigen.
Optionen
| Boardmail an "Vassago" |
Wertpapier: Arrowhead Pharmaceutica |
Recruitment Status : Recruiting
https://clinicaltrials.gov/ct2/show/NCT05677971